MRA在转甲状腺素蛋白淀粉样心肌病疾病修饰治疗患者中的应用
本研究基于TriNetX美国数据库的回顾性队列,纳入4598例接受tafamidis或vutrisiran治疗的ATTR-CM患者,经1:1倾向评分匹配后比较505例MRA使用者与505例非使用者。结果显示MRA使用未显著降低全因死亡或心衰住院复合终点(HR 1.04;95%CI 0.82-1.32;p=0.73),高钾血症风险亦无显著增加。
要点
- 在已接受疾病修饰治疗的ATTR-CM患者中,MRA未显著减少全因死亡或心衰住院。
- MRA使用与全因死亡、心衰住院及室性心律失常风险均无显著关联。
- MRA使用者高钾血症风险未见显著升高(HR 1.13;95%CI 0.89-1.44;p=0.29)。
核心结论
- 在当代接受疾病修饰治疗的ATTR-CM患者队列中,MRA使用带来的增量临床获益有限。
研究设计与样本
- 共纳入4598例患者(平均年龄77.6岁,标准差8.4;男性3726例,占81.0%),其中tafamidis治疗4386例、vutrisiran治疗377例。
- 按1:1倾向评分匹配后,MRA使用者505例与非使用者505例进行比较。
主要发现
- MRA使用与全因死亡或心衰住院复合终点无显著关联(HR 1.04;95%CI 0.82-1.32;p=0.73)。
- 全因死亡风险无显著差异(HR 1.00;95%CI 0.70-1.46;p=0.96)。
- 心衰住院风险无显著差异(HR 1.09;95%CI 0.84-1.43;p=0.48)。
- 室性心律失常风险无显著差异(HR 1.07;95%CI 0.77-1.48;p=0.67)。
- 高钾血症风险在MRA使用者中未见显著升高(HR 1.13;95%CI 0.89-1.44;p=0.29)。
临床怎么用
- 对于已接受tafamidis或vutrisiran治疗的ATTR-CM患者,加用MRA可能不会带来显著的全因死亡或心衰住院获益。
- MRA使用未显著增加高钾血症风险,但临床仍需常规监测血钾。
局限性
- 本研究为回顾性队列设计,可能存在残余混杂。
- 研究基于TriNetX美国数据库,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether mineralocorticoid receptor antagonists (MRAs) confer incremental clinical benefit in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with disease-modifying therapy remains uncertain. We aimed to assess the effectiveness and safety of MRAs in patients with ATTR-CM receiving disease-modifying therapy. METHODS: This retrospective cohort study used data from the TriNetX US database to identify adult patients with ATTR-CM who initiated disease-modifying therapy (tafamidis or vutrisiran) within 1 year of incident heart failure (HF) diagnosis between 1 September 2019 and 10 December 2025. Patients were categorised as MRA users or non-users and were matched based on 1:1 propensity-score matching. The primary effectiveness endpoint was a composite of all-cause mortality or HF hospitalisation (HFH). Secondary effectiveness endpoints were all-cause mortality, HFH and ventricular arrhythmia (VA). The safety endpoint was hyperkalaemia. RESULTS: Among 4598 patients with ATTR-CM (mean (SD) age, 77.6 (8.4) years; 3726 (81.0%) men) treated with tafamidis (n=4386) or vutrisiran (n=377), 505 MRA users were matched to 505 non-users. MRA use was not associated with significant reductions in all-cause mortality or HFH (HR 1.04; 95% CI 0.82 to 1.32; p=0.73). There was no significant difference in all-cause mortality (HR 1.00; 95% CI 0.70 to 1.46; p=0.96), HFH (HR 1.09; 95% CI 0.84 to 1.43; p=0.48) and VA (HR 1.07; 95% CI 0.77 to 1.48; p=0.67). Hyperkalaemia was not significantly higher in MRA users (HR 1.13; 95% CI 0.89 to 1.44; p=0.29) compared with non-users. CONCLUSIONS: In a contemporary cohort of patients with ATTR-CM treated with disease-modifying therapy, MRA use was associated with limited incremental clinical benefits.
引用
- Chi KY, Osabutey A, Lee PL, et al. Mineralocorticoid receptor antagonists in patients with transthyretin amyloid cardiomyopathy receiving disease-modifying therapy. Heart. 2026. PMID: 42567692. doi:10.1136/heartjnl-2026-328038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。